Regulatory Approval / Product Approval
Lupin Receives U.S. FDA Approval for Ranluspec (Ranibizumab), the First Interchangeable Biosimilar Referencing Lucentis in Multiple Formats
NSE
LUPIN
BSE
500257
Lupin Limited announced that the U.S. Food and Drug Administration (FDA) has approved Ranluspec™ (ranibizumab-hkdz), an interchangeable biosimilar referencing Lucentis® (Genentech). The approval covers both vial and pre-filled syringe presentations across approved strengths, strengthening Lupin’s biosimilars portfolio and expanding its presence in the U.S. biologics market.
PRICE-SENSITIVE TRIGGER
Event: U.S. FDA Approval of Ranluspec™ (ranibizumab)
Type: Regulatory Approval / Product Approval
Impact: Positive
Immediate Effect: Lupin can commercialize Ranluspec in the U.S. market as an interchangeable biosimilar to Lucentis, expanding its ophthalmology and biosimilars portfolio while improving access to vision-care therapies.
Key Metrics:
- Product: Ranluspec™ (ranibizumab-hkdz)
- Regulatory Authority: U.S. Food and Drug Administration (FDA)
- Reference Product: Lucentis® (Genentech)
- Product Classification: Interchangeable Biosimilar
- Presentations Approved: Vials and Pre-Filled Syringes (PFS)
- Approved Strengths:
- 0.3 mg (0.05 mL of 6 mg/mL)
- 0.5 mg (0.05mL of 10mg/mL)
Highlight:
- Regulatory Milestone: Ranluspec becomes the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe formats.
What Happened ?
Lupin Limited announced that the U.S. FDA has approved Ranluspec™ (ranibizumab-hkdz) as an interchangeable biosimilar referencing Lucentis® (Genentech). The approval covers both vial and pre-filled syringe presentations in the approved dosage strengths.
Ranibizumab is used in the treatment of several retinal and vision-related disorders, including neovascular (wet) age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion-related macular edema, and myopic choroidal neovascularization.
The approval represents Lupin’s second biosimilar approval in the United States and further strengthens the company’s biologics and specialty pharmaceuticals portfolio.
Key Details
FDA Approval and Strategic Significance:
- U.S. FDA approved Ranluspec™ (ranibizumab-hkdz) as an interchangeable biosimilar to Lucentis®.
- Approval covers both vial and pre-filled syringe (PFS) presentations.
- Both dosage strengths of Lucentis are approved for Ranluspec.
- Ranluspec is currently the only interchangeable ranibizumab biosimilar approved in the U.S. in both delivery formats.
- The therapy targets major retinal disorders and vision-related diseases.
- The approval expands Lupin’s biosimilars portfolio in the United States.
- The product strengthens Lupin’s position in complex biologics and specialty pharmaceuticals.
- The development supports broader patient access to affordable vision-care therapies.
Note:
- Interchangeable biosimilar status is a significant regulatory distinction in the U.S. market, potentially improving physician adoption and market penetration compared with standard biosimilar approvals.
Risk Analysis
Summary:
- Although the FDA approval is a major regulatory achievement, commercial success will depend on market adoption, competitive dynamics, reimbursement coverage, manufacturing execution, and physician acceptance within the ophthalmology market.
Key Risks:
- Competition from branded Lucentis and other biosimilar manufacturers.
- Pricing pressure in the U.S. biosimilars market.
- Reimbursement and formulary inclusion risks.
- Commercial launch execution and supply chain management requirements.
- Market adoption by ophthalmologists and healthcare providers.
Worst Case Scenario:
- Lower-than-expected market penetration or pricing pressure could limit revenue realization despite regulatory approval.
Risk Level: Medium
Company Commentary
- CEO Vinita Gupta stated that the approval strengthens Lupin’s biosimilars portfolio and expands patient access to proven vision therapies.
- Managing Director Nilesh Gupta highlighted the company’s scientific rigor and manufacturing capabilities in advancing scalable biosimilars.
- Dr. Cyrus Karkaria, President – Biotechnology, said the approval validates Lupin’s biologics development expertise and commitment to affordable advanced therapies.
- Management emphasized the strategic importance of biologics and biosimilars as a long-term growth driver.
Official Exchange Filing: Lupin Limited